Apellis reports additional Phase Ib data for C3 inhibitor in PNH
Apellis Pharmaceuticals Inc. (NASDAQ:APLS) reported data from eight evaluable patients with paroxysmal nocturnal hemoglobinuria (PNH) who have not previously received Soliris eculizumab in the open-label, New Zealand Phase Ib PADDOCK trial showing that once-daily 270 mg subcutaneous APL-2 reduced average lactate dehydrogenase (LDH) levels to 225 U/L by day 28 from 2,900 U/L at baseline. Additionally, seven of the eight patients had LDH levels that were below the upper limit of normal at day 28. APL-2 also increased average hemoglobin levels to 12.2 g/dL within 12 weeks from 7.9 g/dL at baseline.
Apellis previously reported data from three evaluable patients in the trial. Additional data are expected in June (see BioCentury, July 7, 2017)...
BCIQ Company Profiles
BCIQ Target Profiles